Comparative Pharmacology
Head-to-head clinical analysis: ACTIVASE versus CATHFLO ACTIVASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACTIVASE versus CATHFLO ACTIVASE.
ACTIVASE vs CATHFLO ACTIVASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tissue plasminogen activator that converts plasminogen to plasmin, degrading fibrin clots.
Tissue plasminogen activator that converts plasminogen to plasmin, leading to fibrinolysis.
Acute ischemic stroke: 0.9 mg/kg IV (max 90 mg) infused over 60 minutes, with 10% of total dose given as IV bolus over 1 minute. Acute myocardial infarction: Total dose of 100 mg administered IV as a 15 mg bolus, then 50 mg infused over 30 minutes, then 35 mg infused over 60 minutes. Pulmonary embolism: 100 mg IV infused over 2 hours.
2 mg via intracatheter instillation, dwell for 2 hours, then aspirate; may repeat once if occlusion persists. For occluded central venous access devices only.
None Documented
None Documented
4-6 minutes initially (alpha phase), then terminal half-life of 20-40 minutes for fibrin-bound alteplase; clinical context: requires continuous infusion.
Initial half-life: 4–6 minutes (alpha phase); terminal half-life: 30–50 minutes (beta phase). Clinical context: Rapid clearance from plasma; effects on fibrinogen depletion persist for 12–24 hours.
Primarily hepatic clearance; renal excretion negligible, <1% unchanged in urine. Fecal elimination unknown as endogenous enzyme.
Primarily hepatic metabolism; renal excretion of inactive metabolites accounts for <5% of the dose. Biliary/fecal elimination is minimal (<1%).
Category C
Category C
Thrombolytic Agent
Thrombolytic Agent